- Joined
- May 7, 2014
- Messages
- 1,652
- Reaction score
- 3,461
Bullet points from CMS Website
Proposals to Address the RO Model Timing and Design
The CY 2022 OPPS and ASC Payment System proposed rule includes the following proposals to modify the RO Model’s timing and design:
Proposals to Address the RO Model Timing and Design
The CY 2022 OPPS and ASC Payment System proposed rule includes the following proposals to modify the RO Model’s timing and design:
- To begin the RO Model on January 1, 2022, with a 5-year Model performance period (ending December 31, 2026).
- To change the baseline period from 2016-2018 to 2017-2019.
- To lower the discounts to 3.5 percent (Professional Component) and 4.5 percent (Technical Component).
- To remove brachytherapy from the list of included modalities under the RO Model so that it would still be paid FFS.
- To revise the cancer inclusion criteria under the RO Model.
- In cases where a beneficiary switches from traditional Medicare to Medicare Advantage during an episode before treatment is complete, CMS would consider this an incomplete episode and RT services would be paid the traditional Medicare rate instead of being paid under the RO Model.
- To adopt an extreme and uncontrollable circumstances policy. This policy would provide flexibility to reduce administrative burden of Model participation, including reporting requirements, and/or adjust the payment methodology as necessary when extreme and uncontrollable circumstances exist.
- To exclude hospital outpatient departments participating in the Community Transformation track of the CHART Model from participation in the RO Model. For the CHART ACO Transformation track, we would follow the same policy for overlap between the RO Model and the Medicare Shared Savings Program ACOs.
- That only hospital outpatient departments that are participating in the Pennsylvania Rural Health Model (PARHM) would be excluded from the RO Model, rather than those that are eligible to participate in PARHM.
- To remove liver cancer from the RO Model as it does not satisfy the model’s cancer inclusion criteria.